Stocklytics Platform
Asset logo for symbol CRL
Charles River Laboratories International
CRL55
$198.61arrow_drop_up2.20%$4.28
S&P500
Asset logo for symbol CRL
CRL55

$198.61

arrow_drop_up2.20%
Key Stats
Open$195.06
Prev. Close$194.32
EPS8.36
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range194.89
198.94
52 Week Range161.64
275.00
Ratios
EPS8.36
Fundamentals
Payout Ratio-
Industry average yield2.96%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CRL-
US Healthcare Sector-
US Market-
check_circle

CRL / Market

CRL exceeded the US Market which returned -0.09% over the last twenty four hours.
check_circle

CRL / Healthcare Sector

CRL exceeded the US Healthcare sector which returned 0.72% over the last twenty four hours.

Charles River Laboratories International (CRL) Statistics

Charles River Laboratories International Inc. (CRL) is a leading global provider of essential products and services to help accelerate the drug discovery and development process. The company offers a wide range of research models and services, including genetically engineered models, clinical laboratory services, discovery and safety assessment services, and manufacturing support services. With over 70 facilities worldwide and a diverse customer base including pharmaceutical, biotechnology, and academic institutions, Charles River Labs is well-positioned to capitalize on the growing demand for outsourcing solutions in the life sciences industry.
In terms of stock statistics, Charles River Labs has consistently delivered strong performance. The company's stock has generated above-average returns for investors, outperforming both the broader market and its sector. Its valuation metrics also reflect its strong financial position. The stock is currently trading at a price-to-earnings ratio that is in line with its sector average, indicating that it is fairly valued. Additionally, Charles River Labs has a solid fundamentals, with positive revenue growth and a healthy profit margin.
add Charles River Laboratories International  to watchlist

Keep an eye on Charles River Laboratories International

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Charles River Laboratories International (CRL) stock's performance compared to its sector and the market over the past year?

Over the past year, Charles River Laboratories International (CRL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 22.23%, Charles River Laboratories International has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 61.01%, it has fallen short of the market average. This comparison highlights Charles River Laboratories International 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Charles River Laboratories International (CRL) stock?

The PE (Price to Earnings) ratio of Charles River Laboratories International (CRL) is currently 23.76. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Charles River Laboratories International (CRL) stock?

The Earnings Per Share (EPS) for Charles River Laboratories International (CRL), calculated on a diluted basis, is $8.36. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Charles River Laboratories International (CRL) stock?

The operating margin for Charles River Laboratories International (CRL) is 16.6%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Charles River Laboratories International (CRL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Charles River Laboratories International (CRL) is $1.01B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Charles River Laboratories International (CRL) have?

Charles River Laboratories International (CRL) has a total debt of $2.84B. The net debt, which accounts for cash and cash equivalents against the total debt, is $2.66B.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media